

Oregon Drug Use Review / Pharmacy & Therapeutics Committee

Thursday, June 4th, 2026

1:05 PM - 3:35 PM

Via Zoom webinar

MEETING MINUTES

NOTE: Any agenda items discussed by the DUR/P&T Committee may result in changes to utilization control recommendations to the OHA. Timing, sequence, and inclusion of agenda items presented to the Committee may change at the discretion of the OHA, P&T Committee, and staff. The DUR/P&T Committee functions as the Rules Advisory Committee to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 in accordance with Oregon Revised Statute 183.333

Members Present: Stacy Ramirez, PharmD; Douglas Carr, MD; Patrick DeMartino, MD; Russ Huffman, PMHNP; Bruce Leewiwatanakul, DO; Eddie Saito, PharmD

Staff Present: Roger Citron, RPh; David Engen, PharmD; Sara Fletcher, PharmD; Andrew Gibler, PharmD; Deanna Moretz, PharmD; Kathy Sentena, PharmD; Sarah Servid, PharmD; Lan Starkweather, PharmD; Brandon Wells; Dee Weston; Trevor Douglass, DC; Lewis Backus

Audience: Lynda Finch*, Biogen; Rober Konop*, Novartis; Abby Hata, Immedica North America; Rodney Padron Perez, Samaritan; Michele Pannell, Alkermes; Jennie Barlow, Amgen; Jenna Doerr, Artia Solutions; Sandee Merrick, Rocket Pharmaceuticals; Tony Pendergraft; Michael Foster, Ultragenyx; Bill McDougall, Biogen; Herbert Starr, Acadia Pharmaceuticals; Lee Stout, Chiesi; Rosalie Elliott, UHA; Gary Parenteau, Dexcom; Elisha Joseph; Jessica GFarrison, Gainwell Technologies; Sergio M; Shauna Wick, Trillium; Tim Melancon; Jason Morris, Samaritan; Lisa Pulver; Nirmal Ghuman; J&J; Daria Meleshkina, Moda EOCCO; Jeanna Colabianchi; Craig Sexton, Supernus; Joseph Auci; Mark Kantor, AllCare; Gloria Zepeda, AllCare; Ann Nelson; Amanda Howton; Divine Marcelo; Chris Ferrin, IHN; Megan Bell; Mike Donabedian, Sarepta Therapeutics; Georgette Dzwilewski, Indivior

(*) Provided verbal testimony

I. CALL TO ORDER

- A. Roll Call & Introductions
 - Meeting called to order at approx. 1:05 p.m., introduction of new Committee member Dr. Leewiwatanakul and roll call of Committee and staff
- B. Conflict of Interest Declaration – no new conflicts of interest were declared
- C. Approval of Agenda and April Minutes presented by Roger Citron, RPh
 - ACTION: Motion to approve, 2nd, all in favor with one abstention**
- D. Department Update provided by Dee Weston, JD
- E. Mental Health Clinical Advisory Group Update presented by Andrew Gibler, PharmD

II. CONSENT AGENDA TOPICS

A. Inhalers for Asthma/COPD Literature Scan

Recommendation:

- No changes to the PDL are recommended based on the review of the clinical evidence
- Evaluate costs in executive session

B. Oncology Prior Authorization (PA) Updates

Recommendation:

- Add: Kitprozy (carfilzomib); Phyrago (dasatinib anhydrous); Zusduri (mitomycin); Lifyorli (relacorilant); Koselugo (selumetinib) to Table 1 in the Oncology Agents PA criteria

C. Orphan Drug Policy Updates

Recommendation:

- Update Table 1 in the Orphan Drugs PA criteria to support medically appropriate use of: Kygevi (doxycitine and doxribitine); Lynavoy (linetrigine); Otarmen (linsitinib); Kresladi (marnetegrone autotemcel); Avlayah (tivicay);
- Modify PA criteria to include new orphan drugs and carve-out status
- Update renewal criteria to accommodate longer approvals for chronic therapy

ACTION: Motion to approve, 2nd, all in favor

III. PDL OLD BUSINESS

A. Healthier Oregon Policy Update

1. Topical Antifungals
2. Antidiarrheals
3. Antacids, Proton Pump Inhibitors
4. Nasal Allergy Inhalers
5. Ophthalmic Medications for Allergies
6. Laxatives for Chronic Constipation

Recommendation:

- Evaluate costs in executive session

ACTION: Motion to approve, 2nd, all in favor

IV. DRUG USE REVIEW (DUR) ACTIVITIES

A. Quarterly Utilization Report: Roger Citron, RPh

B. ProDUR Report: Lan Starkweather, PharmD

C. RetroDUR Report: Dave Engen, PharmD

D. Oregon State Drug Review: Kathy Sentena, PharmD

1. Respiratory Syncytial Virus (RSV) Prevention Update

2. Evaluating the Quality of Evidence from Observational Studies: Lessons from Acetaminophen Use in Pregnancy

V. NEW BUSINESS

A. Topoisomerase II Inhibitors Class Update with New Drug Evaluation: Kathy Sentena, PharmD

Recommendation:

- No changes to the PDL are recommended based on the review of the clinical evidence
- Nonpreferred antibiotics are subject to the **Non-Preferred Drugs in Select PDL Classes** PA criteria
- Maintain zoliflodacin as non-preferred
- Evaluate costs in executive session

ACTION: Motion to approve, 2nd, all in favor

B. Zycubo (Copper Histidinate) Orphan Drug Evaluation: Sara Fletcher, PharmD

Recommendation:

- Implement **Copper histidinate (ZYCUBO)** PA criteria to verify appropriate diagnosis, monitoring and dosing

ACTION: Motion to approve, 2nd, all in favor

C. Benzodiazepines Focused Scan for Catatonia: Dave Engen, PharmD

Recommendations:

- No changes to the PDL are recommended based on the review of the clinical evidence
- Update **Benzodiazepines** PA criteria to align with current evidence for the treatment of catatonia and minimize therapy interruptions for patients with conditions previously approved for long-term use
- Evaluate comparative costs in executive session

ACTION: Motion to approve, 2nd, all in favor

D. Cardamyst (etripamil) New Drug Evaluation: Deanna Moretz, PharmD

Recommendations:

- Maintain etripamil as non-preferred on the PDL
- Implement proposed **Etripamil (Cardamyst) Nasal Spray** PA criteria to ensure appropriate utilization of etripamil nasal spray

ACTION: Modify proposed PA criteria to remove question #6

Motion to approve, 2nd, all in favor

E. Spinal Muscular Atrophy Class Update: Deanna Moretz, PharmD

Recommendations:

- No changes to the PDL are recommended based on the review of clinical evidence
- Revise the **Spinal Muscular Atrophy Drugs** PA criteria to include onasemnogene abeparvovec-brve
- Evaluate drug costs in the executive session

Public Comment: Robert Konop, Novartis; Lynda Finch, Biogen

ACTION: Motion to approve, 2nd, all in favor



Drug Use Research & Management Program

OHA Health Systems Division

500 Summer Street NE, E35; Salem, OR 97301-1079

College of Pharmacy Phone 503-947-5220 | Fax 503-947-1119

F. Myasthenia Gravis DERP Report: Sara Fletcher, PharmD

Recommendations:

- No changes to the PDL or PA criteria are recommended based on the review of clinical evidence
- Update **Amifampridine** and **Efgartigimod** PA criteria as proposed
- Evaluate drug costs in the executive session

ACTION: Motion to approve, 2nd, all in favor

G. Loargys (pegzilarginase) Orphan Drug Evaluation: Deanna Moretz, PharmD

Recommendations:

- Implement proposed **Pegzilarginase-nbln (Loargys®) Injection** PA criteria to ensure use in appropriate FDA-approved populations

Public Comment: Abby Hata, Immedica North America

ACTION: Motion to approve, 2nd, all in favor

VI. EXECUTIVE SESSION

Members Present: Stacy Ramirez, PharmD; Douglas Carr, MD; Patrick DeMartino, MD; Russ Huffman, PMHNP; Bruce Leewiwatanakul, DO; Eddie Saito, PharmD

Staff Present: Roger Citron, RPh; David Engen, PharmD; Sara Fletcher, PharmD; Andrew Gibler, PharmD; Deanna Moretz, PharmD; Kathy Sentena, PharmD; Sarah Servid, PharmD; Lan Starkweather, PharmD; Brandon Wells; Lewis Backus

VII. RECONVENE for PUBLIC RECOMMENDATIONS

A. Inhalers for Asthma/COPD

Recommendation:


- **SABA:** Make levalbuterol HFA, Xopenex HFA, and levalbuterol nebulizer preferred
- **LABA:** Make Striverdi Respimat and arformoterol nebulizer preferred and Serevent Diskus non-preferred
- **ICS/LABA:** Make Dulera and Airduo Respiclick non-preferred
- **LABA/LAMA:** Make Bevespi Aerosphere preferred
- **ICS:** Make budesonide nebulizer and fluticasone HFA preferred; beclomethasone dipropionate AER w/ADAP non-preferred; Pulmicort Flexhaler, Arnuity Ellipta, and Qvar Redihaler non-preferred

ACTION: Motion to approve, 2nd, all in favor

B. Healthier Oregon Policy Update

Recommendation:

- **Topical antifungals:** Make generic tolnafate cream and powder, ciclopirox shampoo, nystatin powder, nystatin/triamcinolone ointment, econazole nitrate cream, terbinafine cream, butenafine cream, clotrimazole solution preferred



- **Antidiarrheals:** Make generic diphenoxylate/atropine tablets and bismuth subsalicylate tablets, chew tabs, and oral suspension preferred
 - **PPIs:** Make omeprazole magnesium DR capsules, omeprazole and omeprazole magnesium DR tablets, and omeprazole DR rapid tabs, esomeprazole magnesium DR tablet, omeprazole-sodium bicarbonate capsule preferred
 - **Laxatives:** Make lubiprostone capsule, prucalopride succinate tablets, polyethylene glycol 3350 powder packs, methylcellulose powder (Citrucel), and senna leaf extract chew tabs preferred
 - **Nasal allergy inhalers:** Make ipratropium bromide spray, triamcinolone acetonide spray, fluticasone propionate spray susp, and budesonide spray/pump preferred
 - **Ophthalmics for allergy:** Make ketotifen fumarate drops preferred
- ACTION: Motion to approve, 2nd, all in favor**

C. Topoisomerase II Inhibitors Class

Recommendations:

- Make no changes to the PDL

ACTION: Motion to approve, 2nd, all in favor

D. Benzodiazepines

Recommendations:

- Make alprazolam rapid tabs, alprazolam intensol (oral concentrate), and Loreev XR voluntary non-preferred
- Make all other benzodiazepines preferred

ACTION: Motion to approve, 2nd, all in favor

E. Spinal Muscular Atrophy

Recommendations:

- Make Zolgensma and high-dose nusinersen (28 mg and 50 mg) vials non-preferred

ACTION: Motion to approve, 2nd, all in favor

F. Myasthenia Gravis

Recommendations:

- Remove PDL status for myasthenia gravis drugs in orphan class (eculizumab [all versions], zilucoplan)
- Make efgartigimod alfa-hyaluronidase qvfc nonpreferred

ACTION: Motion to approve, 2nd, all in favor

VIII. ADJOURN